These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 19608672

  • 21. Substrate reduction therapy.
    Platt FM, Jeyakumar M.
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [Abstract] [Full Text] [Related]

  • 22. Goal-oriented therapy with miglustat in Gaucher disease.
    Pastores GM, Giraldo P, Chérin P, Mehta A.
    Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
    [Abstract] [Full Text] [Related]

  • 23. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F, Grisolia M, Sestito S, Falvo F, Moricca MT, Concolino D.
    J Med Case Rep; 2017 Jan 20; 11(1):19. PubMed ID: 28103924
    [Abstract] [Full Text] [Related]

  • 24. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E, Kose M, Kagnici M, Ucar SK, Sozmen EY, Coker M.
    Blood Cells Mol Dis; 2018 Feb 20; 68():180-184. PubMed ID: 28111116
    [No Abstract] [Full Text] [Related]

  • 25. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C.
    Philos Trans R Soc Lond B Biol Sci; 2003 May 29; 358(1433):955-60. PubMed ID: 12803929
    [Abstract] [Full Text] [Related]

  • 26. Treatment of Gaucher's disease with OGT 918.
    Mistry PK.
    Lancet; 2000 Aug 19; 356(9230):676-7. PubMed ID: 10968454
    [No Abstract] [Full Text] [Related]

  • 27. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M.
    J Inherit Metab Dis; 2006 Aug 19; 29(2-3):449-56. PubMed ID: 16763917
    [Abstract] [Full Text] [Related]

  • 28. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct 19; 14(79):168-70. PubMed ID: 16285070
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 19; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 31. Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.
    Puzo J, Alfonso P, Irun P, Gervas J, Pocovi M, Giraldo P.
    Atherosclerosis; 2010 Apr 19; 209(2):515-9. PubMed ID: 19959168
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Long term differential consequences of miglustat therapy on intestinal disaccharidases.
    Amiri M, Naim HY.
    J Inherit Metab Dis; 2014 Nov 19; 37(6):929-37. PubMed ID: 24863482
    [Abstract] [Full Text] [Related]

  • 36. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
    Hughes DA, Ginsberg L, Baker R, Goodwin S, Milligan A, Richfield L, Mehta AB.
    Parkinsonism Relat Disord; 2007 Aug 19; 13(6):365-8. PubMed ID: 17049454
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
    Heitner R, Elstein D, Aerts J, Weely Sv, Zimran A.
    Blood Cells Mol Dis; 2002 Aug 19; 28(2):127-33. PubMed ID: 12064906
    [Abstract] [Full Text] [Related]

  • 39. Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat.
    Sedel F, Chabrol B, Audoin B, Kaphan E, Tranchant C, Burzykowski T, Tourbah A, Vanier MT, Galanaud D.
    J Neurol; 2016 May 19; 263(5):927-936. PubMed ID: 26984608
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.